Square Pharmaceuticals PLC. (DSE:SQURPHARMA)
Bangladesh · Delayed Price · Currency is BDT 210.30
-0.10 (-0.05%)
At close: May 6, 2026
DSE:SQURPHARMA Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 83,527 | 76,288 | 70,101 | 60,708 | 57,598 | 50,703 | |
Revenue Growth (YoY) | 10.11% | 8.83% | 15.47% | 5.40% | 13.60% | 10.52% |
Cost of Revenue | 42,919 | 40,377 | 37,548 | 32,473 | 28,719 | 25,470 |
Gross Profit | 40,607 | 35,911 | 32,553 | 28,235 | 28,879 | 25,233 |
Selling, General & Admin | 19,049 | 16,756 | 14,571 | 11,689 | 12,118 | 10,034 |
Other Operating Expenses | -202.91 | -238.08 | 8.1 | -144.4 | -98.27 | -69.57 |
Operating Expenses | 18,846 | 16,518 | 14,579 | 11,545 | 12,019 | 9,965 |
Operating Income | 21,761 | 19,393 | 17,974 | 16,690 | 16,860 | 15,269 |
Interest Expense | -117.46 | -214.8 | -244 | -118.97 | -0.03 | -0.01 |
Interest & Investment Income | 8,571 | 6,209 | 4,645 | 3,957 | 3,004 | 3,137 |
Earnings From Equity Investments | 2,695 | 3,194 | 2,595 | 2,523 | 2,011 | 1,291 |
Currency Exchange Gain (Loss) | 124.65 | 308.43 | 346.52 | 650.1 | 451.34 | 19.42 |
Other Non Operating Income (Expenses) | -1,508 | - | - | - | - | 34.43 |
EBT Excluding Unusual Items | 31,527 | 28,889 | 25,316 | 23,701 | 22,325 | 19,751 |
Gain (Loss) on Sale of Investments | - | - | - | - | 384.59 | 177.04 |
Gain (Loss) on Sale of Assets | -8.69 | - | - | -79.8 | 53.49 | - |
Other Unusual Items | - | 0.93 | 0.26 | 0.62 | 0.72 | 32.06 |
Pretax Income | 31,518 | 28,890 | 25,316 | 23,622 | 22,764 | 19,960 |
Income Tax Expense | 5,652 | 4,919 | 4,389 | 4,642 | 4,607 | 4,013 |
Earnings From Continuing Operations | 25,866 | 23,971 | 20,927 | 18,980 | 18,157 | 15,947 |
Minority Interest in Earnings | -3.69 | -3.12 | -1.61 | -0.24 | 0.03 | - |
Net Income | 25,863 | 23,968 | 20,926 | 18,980 | 18,157 | 15,947 |
Net Income to Common | 25,863 | 23,968 | 20,926 | 18,980 | 18,157 | 15,947 |
Net Income Growth | 10.04% | 14.54% | 10.25% | 4.53% | 13.86% | 19.42% |
Shares Outstanding (Basic) | 886 | 886 | 886 | 886 | 886 | 886 |
Shares Outstanding (Diluted) | 886 | 886 | 886 | 886 | 886 | 886 |
Shares Change (YoY) | 0.01% | - | - | - | - | - |
EPS (Basic) | 29.18 | 27.04 | 23.61 | 21.41 | 20.48 | 17.99 |
EPS (Diluted) | 29.18 | 27.04 | 23.61 | 21.41 | 20.48 | 17.99 |
EPS Growth | 10.03% | 14.54% | 10.25% | 4.53% | 13.86% | 19.42% |
Free Cash Flow | 13,979 | 11,125 | 14,348 | 5,685 | 6,692 | 7,178 |
Free Cash Flow Per Share | 15.77 | 12.55 | 16.18 | 6.41 | 7.55 | 8.10 |
Dividend Per Share | 12.000 | 12.000 | 11.000 | 10.500 | 10.000 | 6.000 |
Dividend Growth | 9.09% | 9.09% | 4.76% | 5.00% | 66.67% | 34.04% |
Gross Margin | 48.62% | 47.07% | 46.44% | 46.51% | 50.14% | 49.77% |
Operating Margin | 26.05% | 25.42% | 25.64% | 27.49% | 29.27% | 30.11% |
Profit Margin | 30.96% | 31.42% | 29.85% | 31.26% | 31.52% | 31.45% |
Free Cash Flow Margin | 16.73% | 14.58% | 20.47% | 9.37% | 11.62% | 14.16% |
EBITDA | 23,972 | 21,594 | 20,293 | 19,000 | 18,695 | 17,151 |
EBITDA Margin | 28.70% | 28.31% | 28.95% | 31.30% | 32.46% | 33.83% |
D&A For EBITDA | 2,211 | 2,201 | 2,319 | 2,310 | 1,835 | 1,882 |
EBIT | 21,761 | 19,393 | 17,974 | 16,690 | 16,860 | 15,269 |
EBIT Margin | 26.05% | 25.42% | 25.64% | 27.49% | 29.27% | 30.11% |
Effective Tax Rate | 17.93% | 17.03% | 17.34% | 19.65% | 20.24% | 20.10% |
Revenue as Reported | - | - | - | - | 57,598 | 50,703 |
Advertising Expenses | - | 8.69 | 1.18 | 961.42 | 3.61 | 3.01 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.